Associated Papers
Dolutegravir metabolism: impact of genetic variations on uridine diphosphate glucuronosyltransferase subfamilies.
Tagawa K et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2025
A single nucleotide polymorphism-based formula to predict the risk of propofol TCI concentration being over 4 µg mL-1 at the time of loss of consciousness.
Zheng Z et al.
The Pharmacogenomics Journal, 2022
Clinical Importance of Potential Genetic Determinants Affecting Propofol Pharmacokinetics and Pharmacodynamics.
Budic I et al.
Frontiers in Medicine, 2022
Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine.
Paulík A et al.
Tumori, 2020
The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children.
Pavlovic D et al.
Pharmacogenomics and Personalized Medicine, 2020
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
de Man FM et al.
Clinical Pharmacokinetics, 2018
Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety.
Tucci JD et al.
Pharmacogenetics and Genomics, 2018
Longrange PCR-based next-generation sequencing in pharmacokinetics and pharmacodynamics study of propofol among patients under general anaesthesia.
Zakerska-Banaszak O et al.
Scientific Reports, 2017
The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants.
Yang ZZ et al.
Acta Pharmacologica Sinica, 2017
The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia.
Mikstacki A et al.
Journal of Applied Genetics, 2017
Inter-isoform Hetero-dimerization of Human UDP-Glucuronosyltransferases (UGTs) 1A1, 1A9, and 2B7 and Impacts on Glucuronidation Activity.
Yuan LM et al.
Scientific Reports, 2016
Dimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities.
Liu YQ et al.
Scientific Reports, 2016
Association of the CYP2B6 c.516G>T polymorphism with high blood propofol concentrations in women from northern Greece.
Mastrogianni O et al.
Drug Metabolism and Pharmacokinetics, 2014
Genotype and allele frequencies of polymorphic UGT1A9 in the Polish population.
Zakerska O et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2013
Pharmacogenetics in perioperative medicine.
Cohen M et al.
Current Opinion in Anaesthesiology, 2012
Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen.
Wang H et al.
Biochemical Pharmacology, 2011
Compound heterozygote of a novel missense mutation (p.K402T) and a double missense mutation (p.[G71R;Y486D]) in type II Crigler-Najjar syndrome.
Maruo Y et al.
Journal of Pediatric Gastroenterology and Nutrition, 2011
[Pharmacogenomics for adverse drug reactions].
Saito Y et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine, 2010
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.
Ramírez J et al.
Future Oncology (london, England), 2010
Prediction of deleterious non-synonymous single-nucleotide polymorphisms of human uridine diphosphate glucuronosyltransferase genes.
Di YM et al.
The Aaps Journal, 2009
Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9).
Takahashi H et al.
Basic & Clinical Pharmacology & Toxicology, 2008
Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms.
Argikar UA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Genotyping panel for assessing response to cancer chemotherapy.
Dai Z et al.
Bmc Medical Genomics, 2008
Variability and function of family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A).
Strassburg CP et al.
Critical Reviews in Clinical Laboratory Sciences, 2008
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.
Fujita K et al.
Cancer Chemotherapy and Pharmacology, 2007
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Minami H et al.
Pharmacogenetics and Genomics, 2007
The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
Lévesque E et al.
Clinical Pharmacology and Therapeutics, 2007
Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.
Mehlotra RK et al.
European Journal of Clinical Pharmacology, 2007
Lack of association between UGT1A7, UGT1A9, ARP, SPINK1 and CFTR gene polymorphisms and pancreatic cancer in Italian patients.
Piepoli A et al.
World Journal of Gastroenterology, 2006
The impact of genomics and proteomics in the clinic: functional genetic polymorphisms and their value in response and toxicity prediction in solid tumours.
Stoehlmacher J
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2006
Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus.
Thomas SS et al.
Human Mutation, 2006
Role of pharmacogenetics in irinotecan therapy.
de Jong FA et al.
Cancer Letters, 2006
Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid.
Hesselink DA et al.
Clinical Pharmacology and Therapeutics, 2005
The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
Kuypers DR et al.
Clinical Pharmacology and Therapeutics, 2005
Pharmacogenetics for individualized cancer chemotherapy.
Efferth T et al.
Pharmacology & Therapeutics, 2005
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Paoluzzi L et al.
Journal of Clinical Pharmacology, 2004
A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity.
Yamanaka H et al.
Pharmacogenetics, 2004
Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.
Villeneuve L et al.
The Journal of Pharmacology and Experimental Therapeutics, 2003
Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
Jinno H et al.
The Journal of Pharmacology and Experimental Therapeutics, 2003
Haplotype structures of the UGT1A gene complex in a Japanese population.
Saeki M et al.
The Pharmacogenomics Journal, 0